August 4 (Tuesday)

Stock Watchlist


How It Works

This StockWatch consists of a list of companies that I believe have the potential to do well this week.

It is essential I make this clear: Not all these companies are going to go up nor are they likely to.

Rather, I delineate that these companies have the potential to do well if and only if certain conditions occur.

StockTalk is not responsible for any loss or mistakes made by an investor. However StockTalk would love your feedback and help on how to better improve this.

Trevena Inc

TRVN (2.94)

TRVN, a clinical stage biopharmaceutical company, jumped 27% on Monday following a great earnings report.

Although Monday showed significant growth, there are some strong bearish indicators.

RSI clearly shows divergence and we can clearly see the volume dropping down to pre-earnings.

However, on the long run TRVN has been on a great uptrend and you can take advantage of the sudden correction which may occur.

Marathon Patient Group Inc

MARA (3.81)

MARA had a massive gap up, closing 89% higher.

Odds are, we see a massive correction. This would be a brilliant way to make profit.

However, if there still is a continuation of the uptrend, then the volatility is sure to provide multiple oppurtunities to profit.

Diamondpeak Holdings Corp

DPHC (12.33)

DPHC spiked up 21% due to a combination of merger acquisitions and earnings.

Prior to Monday, DPHC has extremely low volume.

As such, this has a unique advantage: either we see a 20% correction (which if you put and trade options would be a great trade), or the trend stays which means you can take advantage of the uptrend.

Either way, the possibilities for profit seem viable.

Pitney Bowes Inc

PBI (4.91)

PBI had a great earnigns report and has been in an uptrend for a few days.

Monday we saw a 46% spike

We can see either a correction or a continuation of the uptrend. Keep an eye on the price relative to its moving averages.

Direxion ETF S&P 500 BiotechBull 3X

LABU (60.43)

LABU can be a big hitter this week.

With earnings from major biotech firms, the possibility to explode is very prominent.

We may see a reversal in the trend as LABU is about to cross over its 200-period EMA. It additionally broke through the strong channel down pattern we've been seeing for the past few days.